logo
Share SHARE
FONT-SIZE Plus   Neg

Amgen's PCSK9 Inhibitor Lowers LDL Cholesterol Up To 81%

Amgen Inc. (AMGN) Sunday reported positive results from phase 1b study of AMG 145, an investigational PCSK9 inhibitor, in patients with high cholesterol who were taking statins. The study revealed that multiple doses of the drug significantly reduced LDL, or bad cholesterol, by up to 81 percent compared to placebo in patients on low to moderate doses of statins.

AMG 145 is a fully human monoclonal antibody that inhibits PCSK9, a protein that reduces the liver's ability to remove LDL-C from the blood. High LDL cholesterol is the main contributor to the risk of developing cardiovascular disease.

In the 51-patient study, the subjects who received AMG 145 every two weeks in combination with low to moderate doses of statins had LDL reductions of up to 75 percent versus placebo at sixth week.

Meanwhile, the subjects who received AMG 145 in combination of low to moderate doses of statins every four weeks showed up to a 66 percent reduction in LDL at eighth week.

Patients on high doses of statins who received AMG 145 every two weeks had a reduction in LDL of up to 63 percent versus placebo at sixth week, the company said.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
French car maker Renault SA reported Friday higher profit in its fiscal 2015, with strong growth in automotive profit and revenues. The company announced higher dividend. Looking ahead, for fiscal 2016, Renault expects to increase group revenues at constant exchange rates and improve group operating margin. Shares of Rolls-Royce Holdings Plc were gaining around 13 percent in the morning trading in London after the engine maker reported more-than doubled profit in its fiscal year 2015, with lower one-time items. Underlying earnings were hurt by weakness in Marine markets. Further, the company halved its dividends, and still expects lower revenues next year. German steel giant ThyssenKrupp AG reported a loss in its first quarter, compared to last year's profit as sales and orders were hurt by sharp deterioration in materials businesses. The company said its overall performance in the first quarter was within its full-year forecast corridor. Looking ahead, the company continues to expect higher net income and flat sales for fiscal 2016.
comments powered by Disqus
Follow RTT